| Tap a line for its trend | Currentlast close | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 35,213 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 381 | 381 | 550 | 332 | 109 | ||
| 1,839 | 1,839 | 1,476 | 921 | 543 | ||
| 36,671 | — | — | — | — | ||
| 3,975 | 3,975 | 3,590 | 3,266 | 2,961 | ||
| — | +10.7% | +9.9% | +10.3% | — | ||
| 839 | 839 | 672 | 596 | 474 | ||
| 21.1% | 21.1% | 18.7% | 18.2% | 16.0% | ||
| 648 | 648 | 502 | 434 | 335 | ||
| 503 | 503 | 431 | 425 | 266 | ||
| 12.7% | 12.7% | 12.0% | 13.0% | 9.0% | ||
| ₹24.62 | ₹24.62 | ₹21.10 | ₹20.77 | ₹13.00 | ||
| — | +16.7% | +1.6% | +59.8% | — | ||
| 759 | 759 | 523 | 542 | 516 | ||
| −522 | −522 | −705 | −505 | −245 | ||
| 237 | 237 | −182 | 36.9 | 271 | ||
From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 35,213.4 | |
| - Cash, Equiv & ST Investments | 109.3 | 331.7 | 550.1 | 380.6 | 380.6 | |
| + Total Debt | 543.1 | 921.2 | 1,475.9 | 1,838.5 | 1,838.5 | |
| Enterprise Value | — | — | — | — | 36,671.4 | |
| Revenue | 2,961.4 | 3,265.7 | 3,590.1 | 3,975.1 | 3,975.1 | |
| Growth %, YoY | — | +10.3 | +9.9 | +10.7 | — | |
| EBITDA | 473.8 | 595.7 | 671.5 | 839.4 | 839.4 | |
| Margin % | 16.00 | 18.24 | 18.71 | 21.12 | 21.12 | |
| EBIT | 334.5 | 434.3 | 502.3 | 648.0 | 648.0 | |
| Net Income | 265.6 | 424.5 | 431.1 | 503.1 | 503.1 | |
| Margin % | 8.97 | 13.00 | 12.01 | 12.66 | 12.66 | |
| EPS, Adj (current shares) | 13.00 | 20.77 | 21.10 | 24.62 | 24.62 | |
| Growth %, YoY | — | +59.8 | +1.6 | +16.7 | — | |
| Cash from Operations | 516.3 | 542.1 | 523.0 | 758.6 | 758.6 | |
| Capital Expenditures | -244.8 | -505.3 | -705.3 | -521.9 | -521.9 | |
| Free Cash Flow | 271.4 | 36.9 | -182.3 | 236.7 | 236.7 | |
Figures from the company's filings with NSE
In FY26 its standalone net profit was ₹503 crore on revenue of ₹3,975 crore. Its debt-to-equity ratio was 0.71 on 31 March 2026.
No. Narayana Hrudayalaya had borrowings of ₹1,839 crore on 31 March 2026 (standalone balance sheet), a debt-to-equity ratio of 0.71. Its cash and current investments were ₹624 crore, so its net debt was ₹1,214 crore.
Narayana Hrudayalaya's debt-to-equity ratio was 0.71 on 31 March 2026: borrowings of ₹1,839 crore against total equity of ₹2,597 crore.
Narayana Hrudayalaya's book value per share was ₹127.10 on 31 March 2026: shareholders' equity of ₹2,597 crore divided by the 20.44 crore shares in issue.
Narayana Hrudayalaya's net worth — shareholders' equity in its standalone balance sheet — was ₹2,597 crore on 31 March 2026.
Narayana Hrudayalaya's basic earnings per share (EPS) were ₹24.77 in FY26, against ₹21.23 in FY25.
In 2026, Narayana Hrudayalaya has declared one dividend: ₹4.50 with record date 17 July 2026.
In FY26, Narayana Hrudayalaya's return on equity (ROE) was 21.0% and its return on capital employed (ROCE) was 15.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 21.4% and ROCE 15.2%.
In FY26, Narayana Hrudayalaya generated ₹759 crore of cash from operations and spent ₹522 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹237 crore. In FY25 it was −₹182 crore.
In FY26, Narayana Hrudayalaya earned net profit of ₹503 crore on revenue of ₹3,975 crore, against ₹1,493 crore on ₹9,326 crore for Apollo Hospitals Enterprise. Narayana Hrudayalaya's operating margin was 16.3% (Apollo Hospitals Enterprise 19.6%) and its return on equity 21.0% (Apollo Hospitals Enterprise 16.0%).
In FY26 (April 2025–March 2026), Narayana Hrudayalaya's standalone net profit was ₹503 crore, up 16.7% from ₹431 crore in FY25, on revenue from operations of ₹3,975 crore (up 10.7%). Over three years, from FY23, net profit was up 89.4%.
On FY26 standalone figures, against Apollo Hospitals Enterprise, Max Healthcare Institute and Fortis Healthcare: Narayana Hrudayalaya's operating margin of 16.3% is the third highest of the four (Apollo Hospitals Enterprise 19.6%, Max Healthcare Institute 23.6%, Fortis Healthcare 15.6%; peer average 19.6%); its return on equity of 21.0% is the highest of the four (Apollo Hospitals Enterprise 16.0%, Max Healthcare Institute 8.3%, Fortis Healthcare 2.5%; peer average 8.9%); its revenue growth over three years of 10.3% a year is the lowest of the four (Apollo Hospitals Enterprise 12.6% a year, Max Healthcare Institute 14.7% a year, Fortis Healthcare 19.4% a year; peer average 15.6% a year).
From Narayana Hrudayalaya's own standalone results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Standalone figures from the company's filings with NSE; prices are NSE closing prices.